The global antidepressant drugs market was valued at $15,651.0 million in 2020, and is projected to reach $ 21,004.8 million by 2030, registering a CAGR of 3.0 % from 2021 to 2030.
Depression includes a variety of mental health problems characterized by absence of positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. It is a very common condition that affects 1 in every 5 Americans. There are many factors such as genetic factors, stress and brain chemistry, which leads to depression.
Increase in prevalence of depression, rise in geriatric population, and advancements in R&D activities in the pharmaceutical industry to develop innovative drugs drive the market. Moreover, increase in awareness regarding depression, increase in number of clinical trials, and rise in number of populations suffering from stress fuel growth of the antidepressant drugs market. In addition, rise in number of geriatric population drive growth of the market. This is attributed to the fact that geriatric population is highly vulnerable to depression diseases, owing to social isolation and loneliness, which boosts demand for various antidepressant drug therapies for better health outcomes. According to the Journal of The National Academic of Science, in 2020, it was reported that around one-third of adults above the age of 65 years fell lonely and one fourth of adults above 65 years are socially isolated. In addition, according to the Journal of National Institute on Aging, in February 2022, it was reported that loneliness and social isolation are associated with higher rate of depression.
The key factors that drive growth of the market include increased depression and stress levels as in young generation as well as in older people are more prone to diseases including subsyndromal depression and other stress-related disorders. Other factors such as chronic medical conditions, crimes such as sexual abuse, femicide along other behavioral issues further lead to depression, which, in turn, creates demand for antidepressant drugs. However, lack of availability, awareness in undeveloped economies, along with patent expiration of drugs restrain the market growth.
However, poor efficacy and safety profiles of drugs, preference for non-pharmacological therapies, and increase in number of patent expiration of antidepressants that lead to weak pipeline are expected to hamper the market growth.
The global antidepressant drugs market is segmented on the basis of product, depressive disorder, and region. By product, the market is categorized into tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist & reuptake inhibitors, and others.
On the basis of depressive disorder, it is divided into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Some of the major companies that operate in the global antidepressant drugs market are Alkermes Plc, AbbVie Inc., Eli Lilly And Company, GlaxoSmithKline, Inc., H. Lundbeck A/S, Merck KGAA, Pfizer Inc., Teva Pharmaceutical Industries Ltd. (Actavis Generics), and Takeda Pharmaceutical Limited Company.
Depression includes a variety of mental health problems characterized by absence of positive emotion, low mood, and a range of associated cognitive, physical, emotional, and behavioral symptoms. It is a very common condition that affects 1 in every 5 Americans. There are many factors such as genetic factors, stress and brain chemistry, which leads to depression.
Increase in prevalence of depression, rise in geriatric population, and advancements in R&D activities in the pharmaceutical industry to develop innovative drugs drive the market. Moreover, increase in awareness regarding depression, increase in number of clinical trials, and rise in number of populations suffering from stress fuel growth of the antidepressant drugs market. In addition, rise in number of geriatric population drive growth of the market. This is attributed to the fact that geriatric population is highly vulnerable to depression diseases, owing to social isolation and loneliness, which boosts demand for various antidepressant drug therapies for better health outcomes. According to the Journal of The National Academic of Science, in 2020, it was reported that around one-third of adults above the age of 65 years fell lonely and one fourth of adults above 65 years are socially isolated. In addition, according to the Journal of National Institute on Aging, in February 2022, it was reported that loneliness and social isolation are associated with higher rate of depression.
The key factors that drive growth of the market include increased depression and stress levels as in young generation as well as in older people are more prone to diseases including subsyndromal depression and other stress-related disorders. Other factors such as chronic medical conditions, crimes such as sexual abuse, femicide along other behavioral issues further lead to depression, which, in turn, creates demand for antidepressant drugs. However, lack of availability, awareness in undeveloped economies, along with patent expiration of drugs restrain the market growth.
However, poor efficacy and safety profiles of drugs, preference for non-pharmacological therapies, and increase in number of patent expiration of antidepressants that lead to weak pipeline are expected to hamper the market growth.
The global antidepressant drugs market is segmented on the basis of product, depressive disorder, and region. By product, the market is categorized into tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist & reuptake inhibitors, and others.
On the basis of depressive disorder, it is divided into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Some of the major companies that operate in the global antidepressant drugs market are Alkermes Plc, AbbVie Inc., Eli Lilly And Company, GlaxoSmithKline, Inc., H. Lundbeck A/S, Merck KGAA, Pfizer Inc., Teva Pharmaceutical Industries Ltd. (Actavis Generics), and Takeda Pharmaceutical Limited Company.
KEY BENEFITS FOR STAKEHOLDERS
- The report provides an in-depth analysis of the global antidepressant drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets
- It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
- A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global antidepressant drugs market
KEY MARKET SEGMENTS
By Product
- Tricyclic Antidepressants
- Selective Serotonin Reuptake Inhibitors
- Serotonin Norepinephrine Reuptake Inhibitors
- Monoamine Oxidase Inhibitors
- Serotonin Antagonist and Reuptake Inhibitors
- Others
By Depressive Disorder
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
- Generalized Anxiety Disorder
- Panic Disorder
- Others
By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- Alkermes Plc
- AbbVie Inc
- Eli Lilly and Company
- F Hoffmann-La Roche Ltd
- GlaxoSmithKline, Inc
- H Lundbeck A/S
- Merck KGAA
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd (Actavis Generics)
- Takeda Pharmaceutical Limited Company
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Landscape
Chapter 4: Antidepressant Drugs Market, by Depressive Disorder
Chapter 5: Antidepressant Drugs Market, by Product
Chapter 6: Antidepressant Drugs Market, by Region
Chapter 7: Company Profiles
List of Tables
List of Figures
Executive Summary
According to a new report titled, “antidepressant drugs market by product, and depressive disorder: global opportunity analysis and industry forecast, 2021–2030, the global antidepressant drugs market size was valued at $15.651 billion in 2020, and is estimated to reach $21.004 billion by 2030, growing at a CAGR of 3.0% from 2021 to 2030.Depression affects thoughts, behavior, feelings, and sense of well-being of a person and is caused due to biological, genetics, environment, and psychological factors. Low mood and aversion to physical activity are some of the common symptoms of depression. Depression is more common in women than men. Depression drugs work by fixing chemical imbalance such as lack of serotonin in the brain. Antidepressants help in treatment of depression by maintaining balance of various hormones and chemicals in the brain.
Rise in geriatric population, increase in prevalence of depression, and advancements in R&D activities in the pharmaceutical sector majorly drive the market growth. Furthermore, increase in awareness regarding depression and rise in number of people suffering from stress fuel growth of the antidepressant drugs market. However, poor efficacy and safety profiles of these drugs, preference for non-pharmacological therapies, and increase in number of patent expiration of antidepressants that lead to weak pipeline are expected to hamper the market growth.
Moreover, rise in disposable income and development of the pharmaceutical sector for manufacturing of antidepressant drugs are anticipated to drive growth of the antidepressant drugs market. In addition, expansion of many clinical studies on various types of products to evaluate their safety and efficacy propels growth of the market.
Rise in number of approval for antidepressant products and increase in number of pharmaceutical manufacturing companies are the key factors that further boost growth of the market. In addition, surge in demand for antidepressant drugs propel growth of the market.
The global antidepressant drugs market is segmented into product, depressive disorder, and region. On the basis of product, the market is segregated into tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, and others. The selective serotonin reuptake inhibitors segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to advancements in R&D activities in the healthcare sector and increase in prevalence of major depressive disorder and anxiety disorders.
Depending on depressive disorder, the market is bifurcated into tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, and others. The major depressive disorder exhibited the highest growth in 2020, and is expected to lead during the forecast period, owing to increase in prevalence of major depressive disorder and initiatives taken by governments and private organizations about development of drug.
The COVID-19 outbreak is anticipated to have a positive impact on growth of the global antidepressant drug market. The COVID-19 pandemic has stressed healthcare systems in the world and increased the need for advanced hospitals. Implementation of the spread of COVID-19 infection increased the fear of social isolation, and loneliness, which is the main reason for major depressive disorders. Therefore, the COVID-19 have positive impact on the antidepressant drugs market.
Key Findings Of The Study
- By product, the selective serotonin reuptake inhibitors segment was the highest contributor to the market in 2020
- On the basis of depressive disorder, the major depressive disorder segment dominated the market in 2020, and is expected to continue this trend during the forecast period
- Region wise, North America garnered the largest revenue share in 2020, however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period
- North America garnered a major share of the antidepressant drugs market in 2020, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of depression disorder, increase in number of approvals for antidepressant drugs, presence of key players, and development in R&D activities in the healthcare sector in the region. However, Asia-Pacific is expected to register highest CAGR of 49% from 2021 to 2030, owing to increase in prevalence of mental disorder, rise in awareness about depression, growth in health care expenditures, and increase in number of clinical trials
Companies Mentioned
- Alkermes Plc
- AbbVie Inc.
- Eli Lilly And Company
- GlaxoSmithKline, Inc.
- H. Lundbeck A/S
- Merck KGAA
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd. (Actavis Generics)
- Takeda Pharmaceutical Limited Company.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 215 |
| Published | February 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 15651 million |
| Forecasted Market Value ( USD | $ 21004.8 million |
| Compound Annual Growth Rate | 3.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
